Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleClinical Investigations

Baseline Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2− Breast Cancer

David Groheux, Alice Sanna, Mohamed Majdoub, Patricia de Cremoux, Sylvie Giacchetti, Luis Teixeira, Marc Espié, Pascal Merlet, Anne de Roquancourt, Dimitris Visvikis, Mathieu Hatt, Matthieu Resche-Rigon and Elif Hindié
Journal of Nuclear Medicine June 2015, 56 (6) 824-831; DOI: https://doi.org/10.2967/jnumed.115.154138
David Groheux
1Department of Nuclear Medicine, Saint-Louis Hospital, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alice Sanna
2Department of Statistical Sciences, Saint-Louis Hospital, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mohamed Majdoub
3INSERM, UMR 1101 LaTIM, Brest, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patricia de Cremoux
4Department of Biochemistry, Saint-Louis Hospital, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sylvie Giacchetti
5Breast Diseases Unit, Department of Medical Oncology, Saint-Louis Hospital, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luis Teixeira
5Breast Diseases Unit, Department of Medical Oncology, Saint-Louis Hospital, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc Espié
5Breast Diseases Unit, Department of Medical Oncology, Saint-Louis Hospital, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pascal Merlet
1Department of Nuclear Medicine, Saint-Louis Hospital, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne de Roquancourt
6Department of Pathology, Saint-Louis Hospital, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dimitris Visvikis
3INSERM, UMR 1101 LaTIM, Brest, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mathieu Hatt
3INSERM, UMR 1101 LaTIM, Brest, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthieu Resche-Rigon
2Department of Statistical Sciences, Saint-Louis Hospital, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elif Hindié
7Department of Nuclear Medicine, CHU Bordeaux, University of Bordeaux, Bordeaux, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 56 no. 6 824-831
DOI 
https://doi.org/10.2967/jnumed.115.154138
PubMed 
25883123

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Received for publication January 12, 2015
  • Accepted for publication March 10, 2015
  • Published online June 1, 2015.

Article Versions

  • previous version (April 16, 2015 - 06:57).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2015 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Author Information

  1. David Groheux1,
  2. Alice Sanna2,
  3. Mohamed Majdoub3,
  4. Patricia de Cremoux4,
  5. Sylvie Giacchetti5,
  6. Luis Teixeira5,
  7. Marc Espié5,
  8. Pascal Merlet1,
  9. Anne de Roquancourt6,
  10. Dimitris Visvikis3,
  11. Mathieu Hatt3,
  12. Matthieu Resche-Rigon2 and
  13. Elif Hindié7
  1. 1Department of Nuclear Medicine, Saint-Louis Hospital, Paris, France
  2. 2Department of Statistical Sciences, Saint-Louis Hospital, Paris, France
  3. 3INSERM, UMR 1101 LaTIM, Brest, France
  4. 4Department of Biochemistry, Saint-Louis Hospital, Paris, France
  5. 5Breast Diseases Unit, Department of Medical Oncology, Saint-Louis Hospital, Paris, France
  6. 6Department of Pathology, Saint-Louis Hospital, Paris, France
  7. 7Department of Nuclear Medicine, CHU Bordeaux, University of Bordeaux, Bordeaux, France
  1. For correspondence or reprints contact: David Groheux, Service de Médecine Nucléaire, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, 1 Ave. Claude Vellefaux, 75475 Paris Cedex 10, France. E-mail: dgroheux{at}yahoo.fr
View Full Text

Statistics from Altmetric.com

Cited By...

  • 46 Citations
  • 54 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • 18F-FDG PET/CT for Staging and Restaging of Breast Cancer
    David Groheux, Alexandre Cochet, Olivier Humbert, Jean-Louis Alberini, Elif Hindié, David Mankoff
    Journal of Nuclear Medicine 2016 57 Supplement 1
  • 18F-FDG PET/CT for Monitoring of Treatment Response in Breast Cancer
    Stefanie Avril, Raymond F. Muzic, Donna Plecha, Bryan J. Traughber, Shaveta Vinayak, Norbert Avril
    Journal of Nuclear Medicine 2016 57 Supplement 1
  • 18F-FDG PET/CT radiomic predictors of pathologic complete response (pCR) to neoadjuvant chemotherapy in breast cancer patients
    Panli Li, Xiuying Wang, Chongrui Xu, Cheng Liu, Chaojie Zheng, Michael J Fulham, Dagan Feng, Lisheng Wang, Shaoli Song, Gang Huang
    European Journal of Nuclear Medicine and Molecular Imaging 2020 47 5
  • 18FDG-PET/CT for predicting the outcome in ER+/HER2- breast cancer patients: comparison of clinicopathological parameters and PET image-derived indices including tumor texture analysis
    David Groheux, Antoine Martineau, Luis Teixeira, Marc Espié, Patricia de Cremoux, Philippe Bertheau, Pascal Merlet, Charles Lemarignier
    Breast Cancer Research 2017 19 1
  • Correlation between tumour characteristics, SUV measurements, metabolic tumour volume, TLG and textural features assessed with 18F-FDG PET in a large cohort of oestrogen receptor-positive breast cancer patients
    Charles Lemarignier, Antoine Martineau, Luis Teixeira, Laetitia Vercellino, Marc Espié, Pascal Merlet, David Groheux
    European Journal of Nuclear Medicine and Molecular Imaging 2017 44 7
  • 18F-FDG PET/CT in the early prediction of pathological response in aggressive subtypes of breast cancer: review of the literature and recommendations for use in clinical trials
    David Groheux, David Mankoff, Marc Espié, Elif Hindié
    European Journal of Nuclear Medicine and Molecular Imaging 2016 43 5
  • Integrated 18F-FDG PET/MRI in breast cancer: early prediction of response to neoadjuvant chemotherapy
    Nariya Cho, Seock-Ah Im, Gi Jeong Cheon, In-Ae Park, Kyung-Hun Lee, Tae-Yong Kim, Young Seon Kim, Bo Ra Kwon, Jung Min Lee, Hoon Young Suh, Koung Jin Suh
    European Journal of Nuclear Medicine and Molecular Imaging 2018 45 3
  • Biomarkers of residual disease after neoadjuvant therapy for breast cancer
    Frederique Penault-Llorca, Nina Radosevic-Robin
    Nature Reviews Clinical Oncology 2016 13 8
  • Prognostic value of 18F-FDG PET and PET/CT for assessment of treatment response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis
    Sangwon Han, Joon Young Choi
    Breast Cancer Research 2020 22 1
  • Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET/CT in no special type breast cancer
    Sofia C. Vaz, John Patrick Pilkington Woll, Fatima Cardoso, David Groheux, Gary J. R. Cook, Gary A. Ulaner, Heather Jacene, Isabel T. Rubio, Jan W. Schoones, Marie-Jeanne Vrancken Peeters, Philip Poortmans, Ritse M. Mann, Stephanie L. Graff, Elizabeth H. Dibble, Lioe-Fee de Geus-Oei
    European Journal of Nuclear Medicine and Molecular Imaging 2024 51 9

Article usage

Article usage: April 2015 to April 2025

AbstractFullPdf
Apr 2015297060
May 2015176081
Jun 2015147536104
Jul 20153101237
Aug 20151891528
Sep 201511249
Oct 2015105623
Nov 20151101024
Dec 20151113840
Jan 2016763826
Feb 2016613529
Mar 2016623126
Apr 2016414230
May 2016482627
Jun 2016572632
Jul 2016401920
Aug 2016262317
Sep 2016241519
Oct 2016501922
Nov 2016362021
Dec 201636139
Jan 2017321310
Feb 2017303718
Mar 2017512913
Apr 2017371610
May 2017433319
Jun 201731192
Jul 201719184
Aug 201726144
Sep 201729169
Oct 2017391510
Nov 201734288
Dec 201732345
Jan 201843235
Feb 201831133
Mar 201835275
Apr 201829125
May 201834236
Jun 201843233
Jul 201828205
Aug 201822224
Sep 201836203
Oct 2018332611
Nov 201823154
Dec 201823152
Jan 201944178
Feb 201942244
Mar 201937308
Apr 201929174
May 2019241410
Jun 2019191011
Jul 2019352211
Aug 201924148
Sep 2019231110
Oct 2019181313
Nov 20192121412
Dec 201925118
Jan 202040135
Feb 2020341310
Mar 2020231212
Apr 2020222010
May 2020231715
Jun 202025136
Jul 20201557
Aug 20201743
Sep 2020191310
Oct 2020291112
Nov 202035109
Dec 20202884
Jan 20215119
Feb 2021102527
Mar 2021112617
Apr 2021111512
May 20217207
Jun 202114166
Jul 202182029
Aug 2021161414
Sep 202191213
Oct 202181735
Nov 2021181830
Dec 202171915
Jan 202271311
Feb 202215119
Mar 2022121110
Apr 2022168
May 20226106
Jun 2022101115
Jul 20227219
Aug 20220117
Sep 202251914
Oct 202218209
Nov 20224103
Dec 20228106
Jan 202343013
Feb 20230163
Mar 202343813
Apr 20231203
May 2023387
Jun 20231138
Jul 20230139
Aug 20235136
Sep 20232257
Oct 2023698
Nov 20233139
Dec 20234325
Jan 20244196
Feb 20246178
Mar 20240813
Apr 202431913
May 202417410
Jun 20243237
Jul 202452716
Aug 2024212923
Sep 2024202911
Oct 202442515
Nov 202472610
Dec 20242247
Jan 202562413
Feb 202555816
Mar 202536917
Apr 202556335
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 56 (6)
Journal of Nuclear Medicine
Vol. 56, Issue 6
June 1, 2015
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Baseline Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2− Breast Cancer
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Baseline Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2− Breast Cancer
David Groheux, Alice Sanna, Mohamed Majdoub, Patricia de Cremoux, Sylvie Giacchetti, Luis Teixeira, Marc Espié, Pascal Merlet, Anne de Roquancourt, Dimitris Visvikis, Mathieu Hatt, Matthieu Resche-Rigon, Elif Hindié
Journal of Nuclear Medicine Jun 2015, 56 (6) 824-831; DOI: 10.2967/jnumed.115.154138

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Baseline Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2− Breast Cancer
David Groheux, Alice Sanna, Mohamed Majdoub, Patricia de Cremoux, Sylvie Giacchetti, Luis Teixeira, Marc Espié, Pascal Merlet, Anne de Roquancourt, Dimitris Visvikis, Mathieu Hatt, Matthieu Resche-Rigon, Elif Hindié
Journal of Nuclear Medicine Jun 2015, 56 (6) 824-831; DOI: 10.2967/jnumed.115.154138
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • The Influence of the Amino Acid Transporter LAT1 on Patient Prognosis and the Relationships between Tumor Immunometabolic and Proliferative Features Depend on Menopausal Status in Breast Cancer
  • FDG PET and FES PET Predict PFS on Endocrine Therapy--Response
  • Complete Metabolic Response on Interim 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography to Predict Long-Term Survival in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy
  • 18F-Fluoroestradiol PET to Predict the Response to Neoadjuvant Treatment of Luminal Breast Cancer
  • 18F-FDG PET/CT for Monitoring of Treatment Response in Breast Cancer
  • 18F-FDG PET/CT for Staging and Restaging of Breast Cancer
  • Google Scholar

More in this TOC Section

  • Feasibility of Ultra-Low-Activity 18F-FDG PET/CT Imaging Using a Long–Axial-Field-of-View PET/CT System
  • Cardiac Presynaptic Sympathetic Nervous Function Evaluated by Cardiac PET in Patients with Chronotropic Incompetence Without Heart Failure
  • Validation and Evaluation of a Vendor-Provided Head Motion Correction Algorithm on the uMI Panorama PET/CT System
Show more Clinical Investigations

Similar Articles

Keywords

  • 18FDG-PET/CT
  • SUVmax
  • total lesion glycolysis
  • ER+/HER2– breast cancer
  • neoadjuvant chemotherapy
  • prognosis
SNMMI

© 2025 SNMMI

Powered by HighWire